Physician profile
Stacey Barnes
NPI 1255784500
$5,981.74
in general payments reported to CMS, 2019-2025
45 companies · $547 in 2025
The $547 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,059 · 2022: $1,109 · 2023: $970 · 2024: $1,296 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,813.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,215.39 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $634.67 | 2021-2024 | |
| Astellas Pharma US INC | $528.51 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $519.68 | 2022-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $465.10 | 2021-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.76 | 2021-2024 | Jardiance |
| Lilly USA, LLC | $259.19 | 2021-2023 | Mounjaro, Emgality, Reyvow |
| Abbott Laboratories | $193.32 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $172.80 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $145.53 | 2024 | Recorlev |
| Janssen Pharmaceuticals, INC | $130.39 | 2021-2022 | |
| Glaxosmithkline, LLC. | $124.74 | 2021 | |
| Corium, LLC | $98.11 | 2023-2024 | Azstarys, Adlarity |
| Pfizer INC. | $83.37 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $77.11 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.